This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|August 19, 2019
Parker Bioscience Filtration Expands Single-Use System Facility in UK
Author(s)BioPharm International Editors
The Birtley, UK facility added cleanroom, manufacturing, and testing facilities for biopharma manufacturing single-use systems.
Advertisement
Parker Bioscience Filtration, which supplies automated single-use solutions that include filtration, single-use fluid-handling systems, and sensors, opened expanded facilities at its Birtley, United Kingdom site, including new cleanroom, manufacturing, and testing facilities, the company announced in a Aug. 15, 2019 press release. The SciLog Suite supports process development by providing a facility to test and optimize unit operations within a production process. The facility includes the SciLog FD for bulk drug filtration and dispense, the SciLog TFF for tangential flow filtration operations, and the SciLog NFF for normal flow filtration operations. The facility can accommodate more than 20 people.
Earlier this year, as part of the same investment program, the company
“It’s hugely exciting to have opened the doors to our extended and refurbished site in Birtley. The investment in these facilities demonstrates Parker Hannifin’s commitment to our European customer base and through this, we have strengthened the level of technical support and service that we can offer across biopharmaceutical manufacturing.We have shortened the supply chain for our European customers and made it easier for customers to access filtration solutions and automated systems,” said Kris Holmes, general manager of Parker Bioscience Filtration, in the press release. “In addition, we have also provided a greatly enhanced working environment for Parker Bioscience Filtration’s specialist workforce. The overall investment in our laboratory, cleanroom, manufacturing, office, and warehouse facilities has made our Birtley premises one of the most modern manufacturing sites for integrated bioprocessing solutions in EMEA.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5